Parovirus having a CpG-enriched genome useful for cancer therapy

US10098917B2 · kind B2 · utility

Assignees

• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Zahari Raykov · Heidelberg, DE
• Jean Rommelaere · Heidelberg, DE
• Nathalia Giese · Schriesheim, DE
• Marc Aprahamian · Heidelberg, DE

Key dates

• Filing date: May 3, 2013
• Grant date: Oct 16, 2018
• Expiry date: Nov 28, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14332
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.